Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Trastuzumab |
Indication/Tumor Type | Her2-receptor positive breast cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | Her2-receptor positive breast cancer | predicted - sensitive | Trastuzumab | Phase III | Actionable | In a retrospective analysis of a Phase III trial (KATHERINE), CD274 (PD-L1) expression was associated with invasive disease-free survival (HR=0.66) in patients with Erbb2 (Her2)-positive breast cancer treated with adjuvant Herceptin (trastuzumab), who had residual invasive disease after neoadjuvant therapy (PMID: 36730339; NCT01772472). | 36730339 |
PubMed Id | Reference Title | Details |
---|---|---|
(36730339) | Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer. | Full reference... |